Our first scientific paper on NSKIs has been published, in the prestigious medical journal Inflammatory Bowel Diseases: 

Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative Colitis

Biancheri, Paolo MD; Foster, Martyn R. BSc; Fyfe, Matthew C. T. PhD; MacDonald, Thomas T. PhD; Sirohi, Sameer MSc; Solanke, Yemisi BSc; Wood, Eleanor MB BChir; Rowley, Adele PhD; Webber, Steve PhD; Walshe, Claire A. PhD 

Inflammatory Bowel Diseases: June 2016 - Volume 22 - Issue 6 -p 1306-1315


A review paper has also been published by Matthew C.T. Fyfe, Non-systemic Intestine-Targeted Drugs. In: Geoff Lawton and David R. Witty, editors, Progress in Medicinal Chemistry, Vol. 55, Amsterdam: Elsevier, 2016, pp. 1-44



TopiVert presented the following 3 posters at the leading gastrointestinal industry conference: 12th Congress of ECCO, 15-18 February 2017 in Barcelona. 

  • A first clinical trial of a novel narrow spectrum kinase inhibitor TOP1288 in patients with ulcerative colitis
  • The pharmacological profile of TOP1288, a narrow spectrum kinase inhibitor (NSKI) in clinical development as an anti-inflammatory treatment for ulcerative colitis
  • The narrow spectrum kinase inhibitor (NSKI) TOP1288 Demonstrates Potent Anti-Inflammatory Effects in a T cell Adoptive Transfer Colitis Model through  a Topical Mode of Action

TopiVert also presented the following 5 posters at the 11th Congress of ECCO, 16-19 March 2016 in Amsterstdam